Literature DB >> 28898927

In-hospital 'CODE STEMI' improves door-to-balloon time in patients undergoing primary percutaneous coronary intervention.

Ji Quan Koh1,2, David C Tong1, Rumes Sriamareswaran1, Allysha Yeap1, Bryan Yip1, Sam Wu1, Padeepa Perera1, Shyaman Menon3, Saad Al Noaman3, Jamie Layland1,2.   

Abstract

OBJECTIVE: Reducing time to reperfusion for ST-segment elevation myocardial infarction (STEMI) is essential in improving outcomes. Consequently, numerous strategies have been employed to reduce median door-to-balloon time (DTBT).
METHODS: CODE STEMI is an ED physician-activated STEMI notification system. On activation, an announcement is made over the hospital's public announcement (PA) system. We prospectively analysed all in-hours STEMI patients who had primary percutaneous coronary intervention (PPCI) Pre-CODE STEMI (2014) and after CODE STEMI was implemented (2015). The primary end-points were median DTBT and the proportion of STEMI patients achieving a DTBT ≤90 min. The secondary end-points were in-hospital outcomes, and a composite of major adverse cardiac events (MACE) and hospital readmission rates at 30 days and 12 months.
RESULTS: There were 41 and 42 patients in Pre-CODE STEMI and CODE STEMI groups respectively. Baseline characteristics were similar. DTBT was significantly reduced by 22.1 min from 67.1 ± 34.9 min Pre-CODE STEMI to 45.0 ± 22.7 min (P = 0.001) in the CODE STEMI group. Door-to-door time (DTDT) was also reduced from 46.3 ± 30.9 min to 29.4 ± 23.3 min (P = 0.006). A greater proportion of CODE STEMI patients achieved the target DTBT ≤90 min (95.2% vs 73.2%, P = 0.007). CODE STEMI patients had less systolic dysfunction measured by a left ventricle ejection fraction of ≤40% (10.0% vs 27.8%, P = 0.07). There were trends to lower in-hospital mortality rates (4.8% vs 9.8%, P = 0.43), MACE at 30 days and 12 months (4.8% vs 9.8%, P = 0.43; 11.9% vs 22.0%, P = 0.25).
CONCLUSION: The novel in-hospital in-hours CODE STEMI notification system significantly reduced DTBT in patients undergoing PPCI.
© 2017 Australasian College for Emergency Medicine and Australasian Society for Emergency Medicine.

Entities:  

Keywords:  ST-segment elevation myocardial infarction; door-to-balloon time; primary percutaneous coronary intervention

Mesh:

Year:  2017        PMID: 28898927     DOI: 10.1111/1742-6723.12855

Source DB:  PubMed          Journal:  Emerg Med Australas        ISSN: 1742-6723            Impact factor:   2.151


  5 in total

1.  Targeting an Ischemic Time <120 Minutes in ST-Segment-Elevation Myocardial Infarction.

Authors:  Matthew Henderson; Jaclyn Carberry; Colin Berry
Journal:  J Am Heart Assoc       Date:  2019-06-11       Impact factor: 5.501

2.  Impact in total ischemic time and ST-segment elevation myocardial infarction admissions during COVID-19.

Authors:  Sharon Bruoha; Chaim Yosefy; Enrique Gallego-Colon; Jonathan Rieck; Yan Orlov; Azriel Osherov; Abu Hamed Jihad; Yaniv Sherer; Nasi Viki; Jamal Jafari
Journal:  Am J Emerg Med       Date:  2021-02-18       Impact factor: 2.469

3.  Impact of paramedic education on door-to-balloon times and appropriate use of the primary PCI pathway in ST-elevation myocardial infarction.

Authors:  Kalaivani Mahadevan; Divyesh Sharma; Christopher Walker; Annette Maznyczka; Alex Hobson; Philip Strike; Huw Griffiths; Ali Dana
Journal:  BMJ Open       Date:  2022-02-24       Impact factor: 2.692

4.  CODE STEMI Program Improves Clinical Outcome in ST Elevation Myocardial Infarction Patients: A Retrospective Cohort Study.

Authors:  Eka Ginanjar; Amal C Sjaaf; Idrus Alwi; Wahyu Sulistyadi; Ede Suryadarmawan; Adik Wibowo; Lies Dina Liastuti
Journal:  Open Access Emerg Med       Date:  2020-11-02

5.  Reduction of door-to-balloon time in patients with ST-elevation myocardial infarction by single-catheter primary percutaneous coronary intervention method.

Authors:  Kyong Hee Lee; Sho Torii; Mitsutoshi Oguri; Tsuyosi Miyaji; Takahiko Kiyooka; Yuujirou Ono; Kouhei Asada; Taichi Adachi; Akihiko Takahashi; Yuji Ikari
Journal:  Catheter Cardiovasc Interv       Date:  2021-05-31       Impact factor: 2.585

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.